Institutional Holdings in Surgical Science Sweden AB (OM:SUS) Signal Mixed Sentiment Amid Price Target Recalibration

2025-12-26 01:36:04

Abstract generation in progress

Surgical Science Sweden AB continues to attract institutional attention despite recent analyst repricing. Currently, 18 funds and institutions maintain positions in the surgical cap technology company, with collective stakes totaling approximately 4,349K shares. This represents a modest 1.61% quarter-over-quarter expansion in institutional ownership, though the number of reporting entities remained flat.

Fund Positioning and Portfolio Allocation

The average institutional portfolio weight allocated to SUS stands at 0.09%, marking a notable 4.03% increase from the prior period. Leading the institutional lineup is SMCWX - SMALLCAP WORLD FUND INC, which maintains 3,271K shares for a 6.41% company stake—unchanged from last quarter. Meanwhile, ARTJX - Artisan International Small-Mid Fund Investor Shares pared its position from 297K to 252K shares (a 17.59% reduction), yet paradoxically increased its relative portfolio allocation by 5.70%.

Other notable stakeholders include IEFA - iShares Core MSCI EAFE ETF with 213K shares (0.42% ownership), which grew its holdings by 1.25% while boosting portfolio weight by 1.35%. FIDELITY SERIES INTERNATIONAL SMALL CAP FUND holds 190K shares (0.37%), maintaining its stakes intact. SCZ - iShares MSCI EAFE Small-Cap ETF rounded out major holders with 118K shares (0.23%), a marginal 0.66% increase offset by a 1.55% portfolio allocation decrease.

Analyst Consensus Adjusts Downward

Analyst sentiment has shifted materially, with the consensus one-year price target for Surgical Science Sweden AB revised downward to 73.44 kr per share—a 32.24% pullback from the prior December 3, 2025 estimate of 108.38 kr. Current analyst forecasts span from 40.40 kr on the low end to 123.90 kr at the high end, reflecting persistent disagreement on valuation.

At the latest closing price of 31.98 kr, the average price target still implies 129.64% upside potential, suggesting analysts retain constructive long-term positioning despite the recent downward revision.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.